DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advi... ( LA JOLLA Calif. June 3 /- DermTec...)

HOME >> BIOLOGY >> TECHNOLOGY

DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board

Date:6/3/2008

LA JOLLA, Calif., June 3 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, today announced that Herbert A. Fritsche, Ph.D., has joined DermTech's Scientific Advisory Board. Dr. Fritsche is Professor and Chief of Clinical Chemistry at M.D. Anderson Cancer Center and one of the world's experts in the development and validation of cancer diagnostics for early disease detection and in the fast-growing area of translational research, moving research into clinical practice.

"We are honored that Dr. Fritsche is joining DermTech's Scientific Advisory Board and we are delighted to welcome him to the company," said George Schwartz, CEO, DermTech. "Dr. Fritsche has been with M.D. Anderson for almost 40 years and is one of the pioneers of today's molecular diagnostic assays for cancer detection and predicting drug response. His expertise will clearly be a major asset to DermTech as we are moving forward at an accelerated pace to develop our first product for the non-invasive early detection of melanoma."

"I am very pleased to become a member of DermTech's SAB and assist the company as it continues to optimize its novel melanoma assay and develops additional diagnostics using its "tape stripping" technology for the early detection of disease," said Herbert A. Fritsche, Ph.D. "This is an exciting time in medicine - in the field of cancer, I predict that within 10 years and maybe less, no major treatment decisions will be made without first consulting a laboratory test. I am looking forward to applying my experience to what I believe will be the next-generation approach to improved cancer detection."

Dr. Fritsche's career at M.D. Anderson includes some of the earliest work in translational research including the development of blood and tissue tests for protein tumor markers (CEA, AFP, HCG, LDH, B2M, estrogen and progesterone receptors), more recently, tests for cir
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Abt Associates Names Richard Small Vice President and Chief Financial Officer
6. Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety
7. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
8. Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
9. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
10. Codexis Names David Anton VP Bioindustrials R&D
11. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors

Post Your Comments:

DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advi...( LA JOLLA Calif. June 3 /- DermTec...)